Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03761914Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersTreatment